TG Therapeutics, Inc. (TGTX): Earnings News

TGTX – Misses EPS loss estimates by $0.02.


Key Facts Surrounding This News Item


  • TGTX had a POWR Rating of A (Strong Buy) coming into today.
  • TGTX was 4.97% above its 10-Day Moving Average coming into today.
  • TGTX was 13.63% above its 20-Day Moving Average coming into today.
  • TGTX was 33.86% above its 50-Day Moving Average coming into today.
  • TGTX was 55.36% above its 100-Day Moving Average coming into today.
  • TGTX was 42.98% above its 200-Day Moving Average coming into today.
  • TGTX had returned +85.98% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About TG Therapeutics, Inc. (TGTX)


TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York. View our full TGTX ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

TGTX at a Glance

TGTX Current POWR Rating™
Overall POWR Rating™
TGTX Current Price $9.05 1.12%
More TGTX Ratings, Data, and News

TGTX Price Reaction

The day of this event (Mar. 8, 2018)
TGTX Closing Price$16.45 7.87%
TGTX Volume2,075,200
19.72% from avg
Leading up to this event
TGTX 1-mo return29.24%
After this event
TGTX 1-day return7.85%
TGTX 3-day return9.23%
TGTX 5-day return7.29%

TGTX Price Chart



More TG Therapeutics, Inc. (TGTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TGTX News
Page generated in 1.1258 seconds.